


**Product Name** : TUL01101  
**Cat. No.** : PC-25034  
**CAS No.** : 2411222-97-2  
**Molecular Formula** : C<sub>22</sub>H<sub>25</sub>F<sub>2</sub>N<sub>5</sub>O<sub>2</sub>  
**Molecular Weight** : 429.47  
**Target** : JAK  
**Solubility** : 10 mM in DMSO



CAS: 2411222-97-2

## Biological Activity

Blovacitinib (TUL01101) is a potent, selective and oral Janus kinase 1 (JAK1) inhibitor with IC<sub>50</sub> of 3 nM, >12-fold selectivity for JAK2 and TYK2.

TUL01101 interacts with JAK1 JH1 domain.

TUL01101 can effectively inhibit signaling pathways involved by JAK1 mediated by IL-6, with stronger inhibitory activity than filgotinib (IC<sub>50</sub>: 125.9 vs 407.4 nM).

TUL01101 can effectively inhibit JAK1-JAK3 signaling pathway mediated by IL-2 and JAK1-TYK2 signaling pathway mediated by IFN $\alpha$ .

TUL01101 does not inhibit JAK2 signaling pathways induced by GM-CSF.

TUL01101 (1 mg/kg, BID, p.o.) exhibited effective activity in the treatment of RA both in collagen-induced arthritis (CIA) and adjuvant-induced arthritis (AIA) models, with low dose and low toxicity.

## References

Shuhao Zhou, et al. J Med Chem. 2022 Dec 22;65(24):16716-16740.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com